Laouari Denise, Burtin Martine, Phelep Aurélie, Martino Carla, Pillebout Evangeline, Montagutelli Xavier, Friedlander Gérard, Terzi Fabiola
INSERM U845, Université Paris Descartes, Team: Mechanisms and therapeutic strategies in chronic nephropathies, Hôpital Necker Enfants Malades, Tour Lavoisier, 6ème étage, 149 Rue de Sèvres, 75015 Paris, France.
J Am Soc Nephrol. 2011 Feb;22(2):327-35. doi: 10.1681/ASN.2010040356. Epub 2010 Dec 23.
The mechanisms of progression of chronic kidney disease (CKD) are poorly understood. Epidemiologic studies suggest a strong genetic component, but the genes that contribute to the onset and progression of CKD are largely unknown. Here, we applied an experimental model of CKD (75% excision of total renal mass) to six different strains of mice and found that only the FVB/N strain developed renal lesions. We performed a genome-scan analysis in mice generated by back-crossing resistant and sensitive strains; we identified a major susceptibility locus (Ckdp1) on chromosome 6, which corresponds to regions on human chromosome 2 and 3 that link with CKD progression. In silico analysis revealed that the locus includes the gene encoding the EGF receptor (EGFR) ligand TGF-α. TGF-α protein levels markedly increased after nephron reduction exclusively in FVB/N mice, and this increase preceded the development of renal lesions. Furthermore, pharmacologic inhibition of EGFR prevented the development of renal lesions in the sensitive FVB/N strain. These data suggest that variable TGF-α expression may explain, in part, the genetic susceptibility to CKD progression. EGFR inhibition may be a therapeutic strategy to counteract the genetic predisposition to CKD.
慢性肾脏病(CKD)进展的机制目前仍知之甚少。流行病学研究表明其存在很强的遗传因素,但导致CKD发病和进展的基因在很大程度上尚不明确。在此,我们将CKD实验模型(切除75%的总肾质量)应用于六种不同品系的小鼠,发现只有FVB/N品系出现了肾脏病变。我们对通过抗性和敏感品系回交产生的小鼠进行了基因组扫描分析;我们在6号染色体上鉴定出一个主要的易感基因座(Ckdp1),它对应于人类2号和3号染色体上与CKD进展相关的区域。计算机分析显示该基因座包含编码表皮生长因子受体(EGFR)配体转化生长因子-α(TGF-α)的基因。仅在FVB/N小鼠中,肾单位减少后TGF-α蛋白水平显著升高,且这种升高先于肾脏病变的发生。此外,EGFR的药物抑制可预防敏感的FVB/N品系中肾脏病变的发展。这些数据表明,TGF-α表达的差异可能部分解释了CKD进展的遗传易感性。EGFR抑制可能是一种对抗CKD遗传易感性的治疗策略。